Registry of patients with relapsed or refractory acute myeloid leukemia treated with Venetoclax
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry
This study is collecting information on patients with relapsed or refractory acute myeloid leukemia who are treated with the drug Venetoclax to see how it works in real-world settings.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Hannover Medical School Academic / other |
| Locations | 1 site (Hannover, Niedersachsen) |
| Trial ID | NCT03662724 on ClinicalTrials.gov |
What this trial studies
This registry aims to systematically document the characteristics, biological profiles, and clinical courses of patients with acute myeloid leukemia (AML) who are treated with the BCL2 inhibitor Venetoclax outside of clinical trials. Data will be collected retrospectively from multiple hospitals participating in the registry, ensuring a standardized approach. The study will also include mutation analysis of patient samples to correlate genetic factors with clinical outcomes.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults diagnosed with relapsed or refractory acute myeloid leukemia who are receiving treatment with Venetoclax.
Not a fit: Patients who are not receiving Venetoclax or those with other forms of leukemia may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of how Venetoclax affects patients with relapsed or refractory AML, potentially leading to improved treatment strategies.
How similar studies have performed: While this registry approach is common, the specific focus on Venetoclax in a real-world setting is relatively novel and may provide valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: relapsed/refractory AML Exclusion Criteria: -
Where this trial is running
Hannover, Niedersachsen
- Medical School Hannover — Hannover, Niedersachsen, Germany (Recruiting)
Study contacts
- Principal investigator: Michael Heuser, MD — Hannover Medical School
- Study coordinator: Michael Heuser, MD
- Email: heuser.michael@mh-hannover.de
- Phone: +49511 5323720
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.